Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 23 clinical trials
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

The purpose of this study is to test the safety of 19(T2)28z1xx CAR T cells in people with relapsed/refractory B-cell cancers. The researchers will try to find the highest dose of 19(T2)28z1xx CAR T cells that causes few or mild side effects in participants. Once they find this dose, they …

anthracycline
biologic agent
stem cell transplantation
lymphoma
monoclonal antibody therapy
  • 0 views
  • 05 Aug, 2020
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

nitrosoureas
recurrent ependymoma
anticancer agents
nitrosourea
cns tumor
  • 0 views
  • 16 Feb, 2024
  • 83 locations
Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

This study was a prospective, multi-center, single-arm, Phase II clinical study. Compared with the literature data, objective response rate (ORR) and complete response rate (CR) were the primary endpoint, and 1-year and 2-year progression-free survival (PFS) and 2-year overall survival (OS) were the secondary endpoint. To evaluate the efficacy and …

  • 0 views
  • 21 Sep, 2021
  • 1 location
Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

This prospectivemulti-centeropen-label, controlled study will evaluate the efficacy and safety of targeted drug in combination with CHOP in treatment of newly diagnosed peripheral T-cell lymphoma.

measurable disease
lymphoma
pet/ct scan
t-cell lymphoma
peripheral t-cell lymphoma
  • 0 views
  • 05 Aug, 2020
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

This prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell lymphoma unfit for conventional chemotherapy.

measurable disease
lymphoma
tucidinostat
azacitidine
chidamide
  • 0 views
  • 16 Feb, 2024
  • 1 location
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

malt
epirubicin
lymphoma
marginal zone lymphoma
prednisone
  • 0 views
  • 05 Aug, 2020
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody combine with Peg-asparaginase and Chidamide regimen for stage IE and IIE ENKTL.

measurable disease
electrocardiogram
neutrophil count
cancer therapy
peg-asparaginase
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy

A study of CT-RD06 cell injection in patients with relapsed or refractory CD19+ B-cell hematological malignancy.

lymphoma
acute lymphoblastic leukemia
hematologic malignancy
chronic lymphocytic leukemia
oximetry
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy

lymphoma
acute lymphoblastic leukemia
b-cell lymphoma
hematologic malignancy
cell transplantation
  • 0 views
  • 16 Feb, 2024
  • 1 location
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

measurable disease
neutrophil count
serum pregnancy test
venetoclax
myd88 gene mutation
  • 0 views
  • 16 Feb, 2024
  • 2 locations